New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
08:11 EDTAGNAllergan outlook has improved, says Wells Fargo
After meeting with Allergan's management, Wells Fargo is more confident in the company's growth momentum and outlook. The firm thinks the company's 2014 guidance is likely conservative, and it keeps an Outperform rating on the shares.
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent AGN news | >>
April 22, 2014
06:51 EDTAGNAllergan fits Valeant criteria, says Cantor
Subscribe for More Information
06:46 EDTAGNAllergan option volume active into Bill Ackman and Valeant Pharmaceuticals bid
Allergan (AGN) option volume of 22K contracts on April 21 was the heaviest volume day in four-months into Bill Ackman and Valeant Pharmaceuticals (VRX) teaming up to make a bid for Allergan. Overall option volatility of 30 is near its 26-week average of 29 according to Track Data. Active volume suggests traders taking positions for large price movement.
06:19 EDTAGNValeant bid for Allergan has 'significant hurdles,' says BMO Capital
Subscribe for More Information
06:11 EDTAGNWells says big pharma bidders could emerge for Allergan
Wells Fargo believes Allergan (AGN) wants to remain independent and says the "hurdle to convince the company to sell could be pretty high." Wells thinks Valeant's (VRX) low tax rate gives it room to raise its bid for Allergan, and it sees the potential for one or more big pharma bidders, such as Johnson & Johnson (JNJ) or Merck (MRK), emerging due to Allergan's "attractive eye care and aesthetics portfolio and pipeline." Wells believes a purchase price for Allergan of $50B or $165 per share could be justified.
05:13 EDTAGNAllergan comments on public filings by Valeant, Pershing Square
Subscribe for More Information
April 21, 2014
19:02 EDTAGNOn The Fly: After Hours Movers
NOTABLE: Allergan (AGN), up 20%, and Valeant Pharmaceuticals (VRX), up 9.1%, both advanced after The Wall Street Journal reported that activist investor Bill Ackman is teaming up with Valeant to make a bid for Allergan. Following the report, Ackman's Pershing Square filed a 13D with the SEC disclosing a 9.7% stake in Allergan and outlining an agreement with Valeant. The agreement, among other things, said that Valeant plans to make a bid for Allergan comprised of $15B of cash and a to-be-determined amount of Valeant stock. The filing also showed that Ackman began building a position in Allergan in late February, and at that time entered an agreement with Valeant forming a new, jointly-owned entity through which to acquire a position in Allergan. CNBC's David Faber reported that Valeant is expected to officially make a hostile bid for Allergan by tomorrow. UP AFTER EARNINGS: Netflix (NFLX) gained 6.3% after reporting profits that beat expectations on revenues that were in-line with expectations. The streaming internet video service also reported that U.S. subscribers grew by 2.25M in the first quarter, with its international subscriber base expanding by 1.75M for the period. DOWN AFTER EARNINGS: Rambus (RMBS) fell 7.5% after providing a second quarter revenue outlook that fell short of expectations, with the company adding that its revenue outlook, "includes expectations that the company will sign new customers for patent as well as solutions licensing." Rambus' first quarter results, however, came in better than expected, and the company also reaffirmed its fiscal 2014 revenue outlook.
17:10 EDTAGNValeant says Ackman can terminate agreement if no Allergan offer by May 2
Subscribe for More Information
17:09 EDTAGNValeant says intends to propose merger with Allergan
Company said in regulatory filing it expects offer to be comprised of $15B of cash with a stock component to be determined.
17:07 EDTAGNValeant, Allergan deal to have $25-$30 per share of synergies, Faber says
CNBC's David Faber is reporting that Valeant's board is meeting tonight regarding a potential bid for Allergan, which it will make in combination with Bill Ackman's Pershing Square. Faber reports that the proposed combination would have about $25-$30 per share in synergies and the offer will 1/3 cash and 2/3 stock.
17:05 EDTAGNAckman reports 9.7% stake in Allergan, to consult with Valeant stake
Bill Ackman's Pershing Square disclosed in a regulatory filing that it holds a 9.7% stake in Allergan (AGN) and that it intends to consult with Valeant (VRX) on its investment. In its filing, Pershing Square said, "Valeant currently intends to propose a merger in which Allergan's shareholders will receive a combination of cash and Valeant common shares. Valeant has not yet determined the amount of cash and number of Valeant common shares it will offer, but it currently expects the cash component will total around $15B. Barclays and Royal Bank of Canada have indicated that they are prepared to deliver financing commitments covering the cash portion of the transaction at the time Valeant makes an offer." Pershing disclosed that on February 25, it entered an agreement with Valeant. As part of the deal, Pershing and Valeant agreed to for a new, jointly owned entity through which they would acquire equity in Allergan. Also, as part of that deal, Pershing Square will acquire $400M of Valeant stock at a 15% discount to current market prices immediately prior to consummation of an offer by Valeant to acquire Allergan. Shares of Allergan remain higher by more than 18% in after hours trade, while Valeant shares are up about 10%.
16:59 EDTAGNPershing Square says intends to consult with Valeant on Allergan investment
16:58 EDTAGNPershing Square says Valeant intends to propose merger with Allergan
Subscribe for More Information
16:57 EDTAGNPershing Square reports 9.7% stake in Allergan
16:40 EDTAGNValeant expected to make hostile bid for Allergan tomorrow, Faber says
Subscribe for More Information
16:38 EDTAGNAckman, Valeant team up on Allergan bid, WSJ says
Subscribe for More Information
16:26 EDTAGNValeant, Bill Ackman team up on Allergan takeover, DJ says
Subscribe for More Information
11:08 EDTAGNAllergan recent rally due to several factors, says BMO Capital
Subscribe for More Information
April 16, 2014
10:00 EDTAGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A10 Networks (ATEN) initiated with a Buy at BofA/Merrill... Actavis (ACT) initiated with a Buy at Sterne Agee... Allergan (AGN) initiated with a Buy at Sterne Agee... Autohome (ATHM) initiated with a Neutral at Credit Suisse... BitAuto (BITA) initiated with an Outperform at Credit Suisse... Centene (CNC) initiated with a Neutral at UBS... Endo International (ENDP) initiated with a Buy at Sterne Agee... FS Investment (FSIC) initiated with an Overweight at Evercore... Hertz (HTZ) initiated with a Buy at Gabelli... Hilton (HLT) initiated with a Hold at Jefferies... Hospira (HSP) initiated with a Neutral at Sterne Agee... ImmunoGen (IMGN) initiated with a Buy at Canaccord... Impax (IPXL) initiated with a Neutral at Sterne Agee... Imperva (IMPV) assumed with a Neutral at Wedbush... Ingredion (INGR) initiated with an Outperform at Credit Suisse... Laredo Petroleum (LPI) initiated with an Outperform at RW Baird... Lpath (LPTN) initiated with a Buy at Canaccord... MediWound (MDWD) initiated with an Outperform at Oppenheimer... Medivation (MDVN) initiated with a Hold at Canaccord... NPS Pharmaceuticals (NPSP) assumed with a Buy at Canaccord... Nimble Storage (NMBL) initiated with a Market Perform at Raymond James... Regeneron (REGN) initiated with a Buy at Canaccord... Salix (SLXP) initiated with a Buy at Sterne Agee... Sibanye Gold (SBGL) initiated with an Outperform at Imperial Capital... Teva (TEVA) initiated with a Neutral at Sterne Agee... Wipro (WIT) assumed with a Hold at Jefferies.
07:04 EDTAGNAllergan initiated with a Buy at Sterne Agee
Target $142.
April 11, 2014
18:44 EDTAGNJ&J halting development of Botox competitor, WSJ says
Subscribe for More Information
1 | 2 | 3 | all recent AGN news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use